ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $551,281 | -12.4% | 26,453 | +0.6% | 0.00% | 0.0% |
| Q2 2023 | $629,503 | +31.7% | 26,284 | +3.5% | 0.00% | +100.0% |
| Q1 2023 | $477,972 | +4.0% | 25,397 | -12.0% | 0.00% | -50.0% |
| Q4 2022 | $459,483 | +4.4% | 28,862 | +7.4% | 0.00% | 0.0% |
| Q3 2022 | $440,000 | +11.4% | 26,869 | -4.1% | 0.00% | +100.0% |
| Q2 2022 | $395,000 | -60.9% | 28,008 | -32.9% | 0.00% | -50.0% |
| Q1 2022 | $1,011,000 | -16.3% | 41,730 | -19.3% | 0.00% | 0.0% |
| Q4 2021 | $1,208,000 | +38.7% | 51,739 | -1.3% | 0.00% | 0.0% |
| Q3 2021 | $871,000 | -44.2% | 52,428 | -18.2% | 0.00% | -60.0% |
| Q2 2021 | $1,562,000 | +148.7% | 64,058 | +163.2% | 0.01% | +150.0% |
| Q1 2021 | $628,000 | -55.9% | 24,339 | -8.6% | 0.00% | -60.0% |
| Q4 2020 | $1,423,000 | +25.9% | 26,618 | -2.9% | 0.01% | 0.0% |
| Q3 2020 | $1,130,000 | -12.8% | 27,401 | +2.5% | 0.01% | -28.6% |
| Q2 2020 | $1,296,000 | +2.9% | 26,733 | -10.4% | 0.01% | -22.2% |
| Q1 2020 | $1,260,000 | -42.5% | 29,828 | -41.8% | 0.01% | -10.0% |
| Q4 2019 | $2,193,000 | +13.7% | 51,254 | -4.3% | 0.01% | -9.1% |
| Q3 2019 | $1,928,000 | +27.0% | 53,583 | -5.7% | 0.01% | +22.2% |
| Q2 2019 | $1,518,000 | -13.9% | 56,801 | -13.5% | 0.01% | -18.2% |
| Q1 2019 | $1,764,000 | +77.5% | 65,695 | +6.8% | 0.01% | +57.1% |
| Q4 2018 | $994,000 | -28.0% | 61,500 | -7.5% | 0.01% | -22.2% |
| Q3 2018 | $1,380,000 | +33.3% | 66,460 | -1.9% | 0.01% | +28.6% |
| Q2 2018 | $1,035,000 | -23.4% | 67,773 | +12.6% | 0.01% | -22.2% |
| Q1 2018 | $1,352,000 | -35.5% | 60,177 | -13.5% | 0.01% | -40.0% |
| Q4 2017 | $2,095,000 | -21.9% | 69,563 | -2.4% | 0.02% | -40.0% |
| Q3 2017 | $2,684,000 | +48.9% | 71,245 | +10.2% | 0.02% | +38.9% |
| Q2 2017 | $1,803,000 | -21.5% | 64,645 | -3.2% | 0.02% | -25.0% |
| Q1 2017 | $2,297,000 | -2.1% | 66,810 | -17.9% | 0.02% | -7.7% |
| Q4 2016 | $2,347,000 | -6.2% | 81,366 | +3.4% | 0.03% | -25.7% |
| Q3 2016 | $2,503,000 | -11.6% | 78,688 | -9.8% | 0.04% | -2.8% |
| Q2 2016 | $2,830,000 | +5.9% | 87,199 | -8.8% | 0.04% | -2.7% |
| Q1 2016 | $2,673,000 | -21.7% | 95,596 | -0.2% | 0.04% | -9.8% |
| Q4 2015 | $3,413,000 | +18.2% | 95,740 | +9.6% | 0.04% | 0.0% |
| Q3 2015 | $2,888,000 | -23.5% | 87,331 | -3.2% | 0.04% | -21.2% |
| Q2 2015 | $3,777,000 | +20.8% | 90,197 | -6.0% | 0.05% | +40.5% |
| Q1 2015 | $3,126,000 | +18.7% | 95,930 | +15.6% | 0.04% | +19.4% |
| Q4 2014 | $2,634,000 | +28.9% | 82,968 | +0.6% | 0.03% | +14.8% |
| Q3 2014 | $2,043,000 | -8.1% | 82,502 | -16.2% | 0.03% | -6.9% |
| Q2 2014 | $2,224,000 | -35.1% | 98,449 | -30.1% | 0.03% | -32.6% |
| Q1 2014 | $3,428,000 | +204.2% | 140,876 | +212.4% | 0.04% | +152.9% |
| Q4 2013 | $1,127,000 | -45.6% | 45,093 | -40.2% | 0.02% | -65.3% |
| Q3 2013 | $2,073,000 | +577.5% | 75,461 | +348.1% | 0.05% | +716.7% |
| Q2 2013 | $306,000 | – | 16,839 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |